Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol Company Has Been Granted a Type C Meeting with the FDA CHAPEL HILL, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today reported financial results for the quarter ended September 30, 2026 and provided an update on recent corporate progress. On August 10, 2026, Tenax announced that LEVEL, the
Detailed price information for Tenax Therapeutics (TENX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Kura Oncology (KURA-Q) from The Globe and Mail including charting and trades.
Tenax Therapeutics, Inc. (NASDAQ:TENX) has a possible route forward for TNX-103, but the Phase 3 LEVEL trial did not establish efficacy in the overall population. The study evaluated oral levosimendan in 241 patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF. At Week 12, the adjusted improvement in six-minute walk […]
CHAPEL HILL, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) announced today that Chris Giordano, President & Chief Executive Officer, will present at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 a.m. ET. The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage. About Tenax TherapeuticsTenax Therapeutics, Inc. is a P
Tenax (TENX) Phase 3 TNX-103 missed endpoints, but subgroup data show improved walking distance in PH-HFpEF.
In patients with a baseline 6MWD below the trial median of 333 meters, treatment with TNX-103 resulted in a 26.3-meter improvement compared to placebo (p = 0.0112) In the same patient population, TNX-103 produced a 47% reduction in NT-proBNP (p < 0.0001) and a 4.9 mmHg reduction in RVSP (p = 0.009) compared to placebo With full statistics analysis now complete, Company confirms TNX-103’s biological effects include marked reductions in pulmonary artery pressure and NT-proBNP, a biomarker reflecti
This is the newest page. Registered accounts read further back.